Mahmoud Hassanein

Mahmoud Hassanein

Auto-generated profile, based on publicly available information

Mahmoud Hassanein

Alexandria University, Alexandria, Egypt

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MCMaria G. Crespo‐Leiro
Maria G. Crespo‐Leiro
SAStefan D. Anker
Stefan D. Anker
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
ACAndrew J. Coats
Andrew J. Coats
GFGerasimos Filippatos
Gerasimos Filippatos
O(on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Aims: The European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT-R) was set up with the aim of describing the clinical epidemiology and the 1-year outcomes of patients with heart failure (HF) with the added intention of comparing differences between participating countries. Methods and results: The ESC-HF-LT-R is a prospective, observational registry contributed to by 211 cardiology centres in 21 European and/or Mediterranean countries, all being member countries of the ESC. Between May 2011 and April 2013 it collected data on 12 440 patients, 40.5% of them hospitalized with acute HF (AHF) and 59.5% outpatients with chronic HF (CHF). The all-cause 1-year mortality rate was 23.6% for AHF and 6.4% for CHF. The combined endpoint of mortality or HF hospitalization within 1 year had a rate of 36% for AHF and 14.5% for CHF. All-cause mortality rates in the different regions ranged from 21.6% to 36.5% in patients with AHF, and from 6.9% to 15.6% in those with CHF. These differences in mortality between regions are thought reflect differences in the characteristics and/or management of these patients. Conclusion: The ESC-HF-LT-R shows that 1-year all-cause mortality of patients with AHF is still high while the mortality of CHF is lower. This registry provides the opportunity to evaluate the management and outcomes of patients with HF and identify areas for improvement.

1 October 2013 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
SAStefan D Anker
Stefan D Anker
UDUlf Dahlström
Ulf Dahlström
GFGerasimos Filippatos
Gerasimos Filippatos
PPPiotr Ponikowski
Piotr Ponikowski
HEHeart Failure Association of the ESC
Heart Failure Association of the ESC
Aims: To evaluate how recommendations of European guidelines regarding pharmacological and non-pharmacological treatments for heart failure (HF) are adopted in clinical practice. Methods and results: The ESC-HF Long-Term Registry is a prospective, observational study conducted in 211 Cardiology Centres of 21 European and Mediterranean countries, members of the European Society of Cardiology (ESC). From May 2011 to April 2013, a total of 12 440 patients were enrolled, 40.5% with acute HF and 59.5% with chronic HF. Intravenous treatments for acute HF were heterogeneously administered, irrespective of guideline recommendations. In chronic HF, with reduced EF, renin–angiotensin system (RAS) blockers, beta-blockers, and mineralocorticoid antagonists (MRAs) were used in 92.2, 92.7, and 67.0% of patients, respectively. When reasons for non-adherence were considered, the real rate of undertreatment accounted for 3.2, 2.3, and 5.4% of the cases, respectively. About 30% of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them. The more relevant reasons for non-implantation of a device, when clinically indicated, were related to doctor uncertainties on the indication, patient refusal, or logistical/cost issues. Conclusion: This pan-European registry shows that, while in patients with acute HF, a large heterogeneity of treatments exists, drug treatment of chronic HF can be considered largely adherent to recommendations of current guidelines, when the reasons for non-adherence are taken into account. Observations regarding the real possibility to adhere fully to current guidelines in daily clinical practice should be seriously considered when clinical practice guidelines have to be written.

28 October 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
GTGiovanni Targher
Giovanni Targher
MDMarco Dauriz
Marco Dauriz
CLCécile Laroche
Cécile Laroche
PTPier Luigi Temporelli
Pier Luigi Temporelli
MHMahmoud Hassanein
Mahmoud Hassanein
OIon behalf of the ESC‐HFA HF Long‐Term Registry investigators
on behalf of the ESC‐HFA HF Long‐Term Registry investigators
Aims The aim of this study was to evaluate the in‐hospital and 1‐year prognostic impact of diabetes and elevated blood glucose levels at hospital admission in patients with acute heart failure (HF). Methods and results We studied a multinational cohort of 6926 hospitalized patients with acute HF enrolled in the European Society of Cardiology (ESC) and Heart Failure Association (HFA) Long‐Term Registry, of whom 49.4% (n = 3422) had known or previously undiagnosed diabetes (defined as self‐reported history, or medication use, or fasting glucose levels ≥7.0 mmol/L or haemoglobin A1c ≥6.5%). Compared with those without diabetes, patients with known or previously undiagnosed diabetes had higher cumulative rates of in‐hospital mortality, 1‐year mortality, and 1‐year HF re‐hospitalization that occurred independently of multiple clinical risk factors: in‐hospital mortality [6.8 vs. 4.4%; adjusted hazard ratio (HR) 1.774; 95% confidence interval (CI) 1.282–2.456, P < 0.001], 1‐year all‐cause mortality (27.5 vs. 24%; adjusted HR 1.162; 95% CI 1.020–1.325, P = 0.024), and 1‐year hospital re‐admissions for HF (23.2 vs. 18.5%; adjusted HR 1.320; 95% CI 1.139–1.530, P < 0.001). Moreover, elevated admission blood glucose concentrations were powerfully prognostic for in‐hospital mortality, but not for 1‐year mortality or re‐hospitalizations, in both patients with and without diabetes. Conclusions Among patients hospitalized for acute HF, the presence of diabetes is independently associated with an increased risk of in‐hospital mortality, 1‐year all‐cause mortality, and 1‐year re‐hospitalizations for HF, underscoring the need for more effective and personalized treatments of diabetes in this particularly high‐risk patient population.

1 April 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
GFGerasimos Filippatos
Gerasimos Filippatos
CAChristiane E. Angermann
Christiane E. Angermann
JCJohn G. F. Cleland
John G. F. Cleland
CLCarolyn S. P. Lam
Carolyn S. P. Lam
UDUlf Dahlström
Ulf Dahlström
SCSean P. Collins
Sean P. Collins
Acute heart failure (AHF) precipitates millions of hospital admissions each year.1-3 Patients with AHF have a variety of underlying heart diseases, risk factors, comorbidities, and precipitants leading to acute decompensation.4-6 Hospitalization for and management of AHF account for the largest proportion of health care resource use in patients living with HF.7,8 Acute and chronic HF management can also affect resource use associated with length of stay (LOS) and early readmission. Furthermore, the route of admission and care pathways (emergency department, ward, or intensive care unit) may affect timing of intravenous therapy for AHF and outcomes.9-11

8 July 2015 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
MHMahmoud Hassanein
Mahmoud Hassanein
MAMagdy Abdelhamid
Magdy Abdelhamid
BIBassem Ibrahim
Bassem Ibrahim
AEAhmed Elshazly
Ahmed Elshazly
MAMohamed Wafaie Aboleineen
Mohamed Wafaie Aboleineen
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
Aims Our aim is to describe the clinical characteristics and management of patients hospitalized with acute heart failure (HHF) and ambulatory patients with chronic heart failure (CHF) in Egypt and compare them with heart failure (HF) patients from other countries in the European Society of Cardiology-Heart Failure (ESC-HF) registry. Methods and results The ESC-HF Long-term Registry is a prospective, multi-centre, observational study of patients presenting to cardiology centres in member countries of the ESC. From April 2011 to February 2014, a total of 2145 patients with HF were recruited from 20 centres all over Egypt. Of these patients, 1475 (68.8%) were hospitalized with HHF, while 670 (31.2%) had CHF. Less than one-third (32.1%) of all patients were females. HHF patients {median age of 61 years [interquartile range (IQR), 53–69]} were older than CHF patients [median age of 57 years (IQR,46-64)]; P < 0.0001. They had more diabetes mellitus (45.4% vs. 31.8%; P < 0.0001). Left ventricular ejection fraction > 45% was present in 22% of HHF vs. 25.6% of CHF (P = 0.17). Atrial fibrillation existed in about a quarter of all patients (24.5%). Ischaemic heart disease was the main cause of HF in Egyptian patients. All-cause in-hospital mortality was 5%. Egyptian patients presented at a much earlier age than in other regions in the registry. They had more diabetes mellitus. Atrial fibrillation prevalence was remarkably lower. Other co-morbidities (renal dysfunction, stroke, and peripheral arterial disease) occurred less frequently. Conclusion Patients in the Egyptian cohort exhibited distinct features from HF patients in other countries in the ESC-HF Long-term Registry.

1 January 2016 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
SASherif Ayad
Sherif Ayad
MHMahmoud M. Hassanein
Mahmoud M. Hassanein
EMElsayed A. Mohamed
Elsayed A. Mohamed
AGAhmed M. Gohar
Ahmed M. Gohar
Background: Pregnancy is associated with several cardiocirculatory changes that can significantly impact underlying cardiac disease. These changes include an increase in cardiac output, sodium, and water retention leading to blood volume expansion, and reductions in systemic vascular resistance and systemic blood pressure. In addition, pregnancy results in a hypercoagulable state that increases the risk of thromboembolic complications. Objectives: The aim of this study is to assess the maternal and fetal outcomes of pregnant women with mechanical prosthetic heart valves (PHVs). Methods: This is a prospective observational study that included 100 pregnant patients with cardiac mechanical valve prostheses on anticoagulant therapy. The main maternal outcomes included thromboembolic or hemorrhagic complications, prosthetic valve thrombosis, and acute decompensated heart failure. Fetal outcomes included miscarriage, fetal death, live birth, small-for-gestational age, and warfarin embryopathy. The relationship between the following were observed: – Maternal and fetal complications and the site of the replaced valve (mitral, aortic, or double) – Maternal and fetal complications and warfarin dosage (≤5 mg, >5 mg) – Maternal and fetal complications and the type of anticoagulation administered during the first trimester Results: This study included 60 patients (60%) with mitral valve replacement (MVR), 22 patients (22%) with aortic valve replacement (AVR), and 18 patients (18%) with double valve replacement (DVR). A total of 65 patients (65%) received >5 mg of oral anticoagulant (warfarin), 33 patients (33%) received ≤5 mg of warfarin, and 2 patients (2%) received low-molecular-weight heparin (LMWH; enoxaparin sodium) throughout the pregnancy. A total of 17 patients (17%) received oral anticoagulant (warfarin) during the first trimester: 9 patients received a daily warfarin dose of >5 mg while the remaining 8 patients received a daily dose of ≤5 mg. Twenty-eight patients (28%) received subcutaneous (SC) heparin calcium and 53 patients (53%) received SC LMWH (enoxaparin sodium). Prosthetic valve thrombosis occurred more frequently in patients with MVR ( P = 0.008). Postpartum hemorrhage was more common in patients with aortic valve prostheses than in patients with mitral valve prostheses ( P 0.005). The incidence of perinatal death was higher in patients with AVR ( P 0.014). The incidence of live birth was higher in patients with DVR ( P 0.012). The incidence of postpartum hemorrhage was higher in patients who received a daily dose of >5 mg of warfarin than in patients who received ≤5 mg of warfarin ( P 0.05). The incidence of spontaneous abortion was also higher in patients receiving >5 mg of warfarin (P ≤ 0.001), while the incidence of live births was higher in patients receiving ≤5 mg of warfarin ( P 0.008). There was a statistically significant difference between the anticoagulant received during the first trimester and cardiac outcomes. Specifically, patients on heparin developed more heart failure ( P 0.008), arrhythmias ( P 0.008), and endocarditis ( P 0.016). There was a statistically significant relationship between heparin shifts during the first trimester and spontaneous abortion ( P 0.003). Conclusion: Warfarin use during the first trimester is safer for the mother but is associated with more fetal loss, especially in doses that exceed 5 mg. The incidence of maternal complications is greater in women who receive LMWH or unfractionated heparin during the first trimester, especially prosthetic valve thrombosis, although the fetal outcome is better because heparin does not cross the placenta.